Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label trial of tusamitamab ravtansine in CEACAM5-positive metastatic breast and pancreatic cancer
NL-OMON51893Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Mar 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of tusamitamab ravtansine in breast cancer and pancreatic adenocarcinoma (PDAC) (3 cohorts), sponsored by Sanofi. Primary endpoints: Objective response rate and Incidence of dose-limiting toxicities. Started Mar 2021; status: active, not recruiting.
02
Drugs
tusamitamab ravtansine
03
Conditions
breast cancerpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON51893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51893.